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Background: Research that explores stigma in Cystic Fibrosis (CF) is limited. Productive cough, repeated lung
infections, and periods of serious illness requiring hospitalizations are among common symptoms of CF. These
symptoms may cause a negative perception by others. We developed a CF-specific Stigma Scale and tested its
psychometric properties.
Methods: We conducted a focus group with 11 participants including adult patients with CF (n = 5) and their
informal caregivers (n = 6). The thematic content of the focus group was analyzed to find key themes. We
developed a CF-specific Stigma Scale and assessed its psychometric properties in a 3-month prospective cohort
study of adult CF outpatients (n = 45).
Results: Stigma emerged as consistent concern for people living and caring for those with CF, affecting both
patients’ lives and health through the focus group. Using the newly developed CF Stigma scale, the mean baseline
score was 16.6 (SD = 4.5, Range = 10-25). The CF Stigma Scale demonstrated robust psychometric properties: 1)
Internal consistency: α = 0.79; 2) Mean inter-item correlation: 0.30 with good test-retest reliability; 3) Convergent
validity: Positive associations with depression, severity of CF symptoms and anxiety; negative associations with
validated quality of life scores were observed.
Conclusions: Stigma is measurable and significantly impacts the lives of CF patients. Further research should
investigate the role of stigma in patients living with CF.
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Cystic Fibrosis (CF) is an inherited, chronic, progressive
and fatal disease [1]. Common symptoms—including
productive cough, repeated lung infections, and periods
of serious illness requiring hospitalizations—may cause
a negative perception by others [2-4]. For patients with
CF, the physical impact, premature mortality, and social
unacceptability of symptoms may be stigmatizing [5].
People living with CF report difficulties with psychological
adjustment and quality of life [6,7] and may experience
emotional disturbances, low self-esteem, feelings of help-
lessness, and depression [8]. Importantly, psychosocial* Correspondence: spakhale@ohri.ca
1Ottawa Hospital Research Institute, 501 Smyth Road, K1H 8 M5 Ottawa,
Ontario, Canada
2The Ottawa Hospital, 501 Smyth Road, K1H 8 M5 Ottawa, Ontario, Canada
Full list of author information is available at the end of the article
© 2014 Pakhale et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.functioning has been linked to impaired pulmonary
function in CF patients [9].
Health-related stigma is defined as a personal experience
with specific characteristics including: exclusion, rejection,
blame, or devaluation resulting from the anticipation of a
negative judgment [10]. Stigma has been demonstrated to
have a significant impact on overall health outcomes and
quality of life [11]. This stigma can interfere with a patient’s
adherence to the intensive treatment regimens required
for chronic conditions such as Human Immunodeficiency
Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS),
Hepatitis C, diabetes, and lung cancer [10,12,13]. For indi-
viduals living with CF, stigma could be associated with
lower adherence to their treatment regimen.
There is very limited research exploring stigma associ-
ated with CF. Pizzignacco and colleagues hypothesize that
in CF patients, stigma could be associated with decreasedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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disease related to decreased morale and this could lead to
a deterioration in lung function, weight and physical func-
tion [14]. The current study was designed to investigate
the relationship between stigma and CF. The objectives of
this study were: 1) to explore if CF patients experience
stigma, 2) to develop/adapt a scale to measure stigma in
CF, and 3) to assess the adapted stigma scale’s psychomet-
ric properties in a prospective, cross-sectional cohort of
adult CF patients. We hypothesized that CF patients will
experience significant health-related stigma measurable by
a CF stigma scale.Methods
This study is a part of a larger project entitled, “The Ottawa
Cystic Fibrosis Treatment Knowledge and Adherence
Program”. We employed a mixed-method design with
two phases: A qualitative phase to better understand the
experience of individuals living with CF and a quantitative
phase to measure stigma in individuals living with CF and
to test the psychometric properties of the scale.
All study procedures (qualitative and quantitative phase)
were approved by the Research Ethics Board of the Ottawa
Hospital Research Institute, Ottawa, Canada. Written in-
formed consent was obtained from all study participants.Qualitative phase
Focus group
A semi-structured, two-hour focus group was conducted
with 11 adults (5 individuals living with CF and their
caregivers) as part of a larger program of research inves-
tigating people caring for and living with CF. The focus
group size was selected such that it was large enough
to gain a variety of perspectives and small enough not
to become disorderly or fragmented. This focus group
obtained accounts of their experience with daily chal-
lenges, stigma, and managing and maintaining adherence
to their complex treatment regimen. We used open-ended
questions related to broad categories based on our clin-
ical knowledge and experience to generate data based
on the synergy of the group interaction. Importantly,
the participants did not know each other, thus encour-
aging more honest and spontaneous expression of views
and a wider range of responses. Data were audiotape re-
corded, transcribed verbatim, and analyzed using The-
matic Analysis as outlined by Braun & Clarke, 2006
[15]. Thematic Analysis included identifying, analyzing
and reporting patterns (themes) within data in order to
minimally organize and describe our dataset in greater
detail. We ensured that the themes were coherent, con-
sistent and distinctive. Themes were then analyzed not
just describing but balancing between analytic narrative
and extracts.Sample size and demographics of focus group participants
Of the 5 participants with CF, 2 were female; all were
Caucasian with post-secondary education and aged 23 to
56 years. Three were employed full time, one part-time,
and the other was on disability. Five of the six caregivers
provided demographic data. They were all female, aged
24 to 55 years, with post-secondary education. We strictly
followed the infection control procedures suggested by
the Canadian Cystic Fibrosis Foundation during the focus
group meeting [16].Results
Preliminary themes identified from the focus group in-
cluded: 1) integrating demands from social, occupational,
and family responsibilities, 2) factors that improve or im-
pede adherence (e.g. lifestyle, social support, personality
style, work), 3) disclosure of CF, 4) navigating the health
care system (e.g. drug insurance, transitioning through
health care providers, fertility treatments), and 5) lack of
knowledge about CF in the general public (e.g. stigma).
Stigma emerged as a consistent concern during the focus
group discussion. Most CF patients in the group noted
that CF symptoms (e.g. coughing) negatively affected
the general public’s reactions. Misconceptions about
CF (e.g. increased lifespan expectations of CF patients
in recent years), lack of awareness (e.g. school’s negative
view of high calorie lunches) and extreme reactions (e.g.
sent home from school for CF cough) were common.
The qualitative phase of the study highlighted the import-
ance of stigma in individuals living with CF. A literature
review revealed no scales to measure CF-specific stigma.
As such, we adapted questions (with permission) from a
well-validated scale, originally designed for HIV patients
[17]. Participants also completed a CF symptom scale
(Pakhale et al., unpublished work).The adapted CF stigma scale
We preserved the original format of the HIV brief
stigma scale [18] owing to its well tested psychometric
properties. The wide ranges of stigma beliefs measured
by the HIV stigma scale are derived from stigmatization
theory. Item responses (“strongly disagree” to “strongly
agree”) are recorded on a 4-point Likert scale, with higher
agreement reflecting endorsement of stigma. Theoretical
scores range from 10 to 40. High internal consistency for
the subscales, ranging between 0.72 and 0.84, is established
[18]. All the HIV items were retained for the CF scale, with
the term ‘CF’ substituted for ‘HIV’ (e.g. “I have been hurt by
how people reacted to learning I have HIV” to “I have been
hurt by how people reacted to learning I have CF”).
Each question in the 10-item scale falls into 1 of 4 do-
mains: Personalized stigma, Disclosure, Public attitudes
and Negative self-image.
Table 1 Study cohort characteristics
Variable Total CF cohort N = 45 (%)








Some university/college 10 (22.2)
University or more 26 (57.8)
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Methods
We conducted an observational cohort study at a multi-
disciplinary adult CF outpatient clinic in Ottawa, Canada.
Participants living with CF were eligible if they were
18 years of age or older, expected to continue receiving
care at the CF clinic for the duration of the study
(1 year), were English speaking and were willing and able
to complete study questionnaires. Participants were ex-
cluded if they had an expected survival of < 1 year as per
CF treatment guidelines or were lung transplant recipients.
A psychological questionnaire package was administered to
participants during a regular clinic visit and a follow-up






Public 15 (33.3)Sample size and demographics of prospective
cross-sectional study
We approached 52 eligible participants; of these, 87%
(n = 45) agreed to participate in the study. Baseline
characteristics of the 45 study participants are presented
in Table 1.Private 22 (55.0)








Married/Steady partner 27 (60)
Divorced 1 (2.2)Recruitment and study questionnaires
The psychological questionnaire package included the
following validated measures:
The Short Form (SF) -12v2 [19]. The SF12v2 is a well
validated self-report measure of quality of life (QoL). It
consists of 12-items that ask patients to rate their
current mental and physical health functioning in the
past 4 weeks on 5-point scales (e.g. “all of the time” to
“none of the time” and “excellent” to “poor”). Higher
scores indicate greater level of QoL. The SF-12v2 has
been found to have good internal consistency with reli-
ability coefficients in the ranges of 0.82 to 0.87 for the
PCS and 0.70 to 0.84 for the MCS in samples of people
living with chronic illnesses (e.g. diabetes, congestive
heart failure) [19].
The CF-specific Quality of Life Questionnaire (CF-specific
QoL) [20]. The CF QoL is a 52-item self-report measure
that assesses both physical and mental health as well as
activities of daily living affected by CF over the past
2 weeks on a 6-point scale (“never” to “all of the time”).
The Centre for Epidemiologic Studies Depression (CES-D)
[21]. The CES-D is a well-validated and widely used
20-item self-report measure that asks participants to
rate the frequency with which they have experienced
symptoms of depression over the past week ranging
from “never” to “almost every day” (e.g. “I felt that every-
thing I did was an effort”).
The Generalized Anxiety Disorder Questionnaire (GAD) -7
[22]. The GAD is a 7-item validated measure used to as-
sess anxiety in the past two weeks.Statistical analysis
Analyses were conducted using the Statistical Package
for Social Sciences (SPSS) software (v18). Data were
screened and statistical assumptions evaluated [23]. We
did not impute missing data; complete case analysis was
performed. Statistical significance was set at p = 0.05
(two-tailed) for all analyses. Mean and standard devi-
ation (SD) of CF stigma scores were assessed at baseline
and at 3 months. Psychometric properties of the CF Stigma
Scale were analyzed using the baseline and 3 month data.
We evaluated face and content validity, test-retest reliability
and convergent validity. Two types of reliability were
estimated on the total score and subscales: Internal
consistency using Cronbach’s alpha coefficients and
test-retest reliability [24]. The latter was calculated by
comparing the consistency of scoring of the new CF Stigma
Scale administered on two occasions (baseline and at
3 months) using a paired samples t-test and Pearson
Table 2 The baseline CF stigma scale scores
Strongly disagree = 1 Disagree = 2 Agree = 3 Strongly agree = 4
N = 45 N (%) N (%) N (%) N (%)
1. I am very careful who I tell that I have CF 6 (13.3) 17 (37.8) 10 (22.2) 11 (24.4)
3. Having CF makes me feel unclean 30 (66.7) 7 (15.6) 6 (13.3) 1 (2.2)
4. Having CF makes me feel that I’m a bad person 37 (82.2) 6 (13.3) 1 (2.2) -
5. Most people think that a person with CF is disgusting 25 (55.6) 13 (28.9) 6 (13.3) -
6. Most people with CF are rejected when others find out 23 (51.1) 19 (42.2) 2 (4.4) -
7. I have been hurt by how people reacted to learning I have CF 22 (48.9) 11 (24.4) 2 (4.4) 1 (2.2)
8. I have stopped socializing with some people because of their
reactions to my having CF
23 (51.1) 13 (28.9) 7 (15.6) -
10. I worry that people who know I have CF will tell others 23 (51.1) 15 (33.3) 4 (8.9) 2 (4.4)
Note: Higher agreement reflects higher stigma experienced by patient.
Table 3 Psychometric properties of the newly adapted
stigma scale
Validity Correlations
CES-D (n, r, p-value) n= 44, r= 0.529, p< .001
GAD-7 (n, r, p-value) n= 39, r= 0.371, p= .014
CF symptom (n, r, p-value) n= 44, r= 0.479, p= .001
SF- 12 (n, r, p-value) n= 44, r=−.454, p= .002
CF-specific QOL
(n, r, p-value)
n= 39, r=−.645, p< .001
Reliability






r = 0.78; p < .001
Baseline Follow-up p-value
Mean differences between
response items (mean, SD)
16.6 (4.5) 16.9 (5.1) 0.3
Center for Epidemiologic Study-Depression scale (CES-D).
Cystic Fibrosis symptom scale (CF symptom).
General Anxiety Disorder −7 scale (GAD-7).
Short Form (SF)-12.
Cystic Fibrosis-specific Quality of Life (CF-specific QOL).
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CF symptoms and quality of life, we conducted post-hoc
tests that consisted of a mediational model hypothesizing
that experiencing more symptoms leads to a reduced
quality of life because of the simultaneous experience of
stigma associated with CF symptoms. Due to the relatively
small sample size of this study, we used bootstrapping
(1000 resamples) to reliably estimate indirect effects, and
avoid concerns regarding requisite assumptions for com-
mon parametric tests such as regression. The Preacher
and Hayes SPSS Macro for Simple Mediation was used for
this analysis [25]. A student t-test was performed to com-
pare the stigma scale scores in our adapted CF Stigma Scale
to the HIV Stigma Scale scores published by Logie and col-
leagues [26].
Results
The CF Stigma Scale scores are depicted in Table 2. Mean
CF stigma scores were 16.6 (SD = 4.5, Range = 10–25) at
baseline and 16.9 (SD = 5.1, Range = 10–28) at follow-up.
The CF Stigma Scale exhibited promising psychometric
properties including very good test-retest reliability over a
3 month period and excellent construct validity (Table 3).
No items demonstrated ceiling effects, and a satisfactory
range and distribution of item responses was observed. In
terms of reliability (Table 3), the CF Stigma Scale demon-
strated adequate internal consistency, with a coefficient
alpha of 0.79, and a mean inter-item correlation of 0.30
(n = 44). Three month test-retest correlations (n = 35) were
good (r = 0.780, p < 0.001). A paired sample t-test revealed
there were no significant differences between responses
to items at study baseline (M = 16.6 ± 4.5) and at time
two (M = 16.9 ± 5.1), t (33) = −1.065, p = 0.30). There
was evidence of strong convergent validity (Table 3).
The CF Stigma Scale scores correlated positively with
symptoms of depression (n = 44, r = 0.529, p < 0.001),
generalized anxiety (n = 39, r = 0.371, p = 0.014), and the
severity of CF symptoms (n = 44, r = 0.479, p = 0.001).
The CF Stigma Scale score was negatively correlated withgeneric quality of life scores (n = 44, r = −0.454, p = 0.002)
and CF-specific quality of life scores (n = 39, r = −0.645,
p < 0.001).
Post hoc tests: stigma as a mediator of symptoms and
quality of life
Based on the observed relationships between CF Stigma
Scale scores, CF symptom scale scores, and quality of
life, we created a model to test the hypothesis that in-
creases in severity of CF symptoms are associated with de-
creased quality of life and this is mediated by the stigma
experience in CF patients (Figure 1). We observed a sig-
nificant positive relationship between reported symptoms
as measured by the CF symptom scale, and experienced
stigma, as assessed by the CF Stigma Scale (p = 0.003); a
Figure 1 Unstandardized regression coefficients for the relationship between CF symptoms and quality of life as mediated by stigma.
The unstandardized regression coefficient between CF symptoms and quality of life, controlling for stigma is in parentheses. This analysis
demonstrates that stigma is a significant mediator between reported CF symptoms and quality of life. *p < .01; **p < .001.
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quality of life (p < 0.001); and a significant negative rela-
tionship between CF stigma and quality of life (p < 0.001).
Although the relationship between symptoms and quality
of life remained significant (p < 0.001), accounting for the
effects of stigma reduced the magnitude of this relation-
ship. This result indicated partial mediation, whereby the
effect of stigma accounted for some, but not all of the
variability in quality of life due to experienced symptoms.
(p = 0.0161). We employed bootstrapping (1000 resamples)
owing to the small sample and confirmed a significant
effect of mediation (M = −0.26, SE = 0.11, 95% CI −0.51
to −0.08). As Figure 1 illustrates, the unstandardized re-
gression coefficient between CF symptoms and quality
of life decreased when controlling for stigma.
Discussion
Stigma is emerging as an important variable to be con-
sidered when working with individuals living with CF.
Complex ongoing care, lifelong symptoms, and the in-
heritable nature of the disease leave adults living with
CF vulnerable to the effects of stigma surrounding their
disease. This is the first study to investigate stigma in CF
and we provide a psychometrically sound tool for evaluat-
ing this. Using a mixed-methods design, we demonstrated
that quality of life is significantly impacted by patients’
experienced symptoms as a result of their experiencedTable 4 Comparison of mean CF scores with mean HIV scores
Domains CF population N = 45 (mean, SD)
Overall 16.6 (4.5)
Sub scales
Personalized stigma* 1.6 (1.4)
Disclosure# 2.1 (0.9)
Negative self-image¥ 1.1 (0.5)
Public attitudes$ 2.6 (1.0)
Note: *Q’s 7, 8, 9 in CF stigma scale; #Q’s 1 and 10 in CF stigma scale; ¥Q’s 2, 3 and 4stigma. Comparing our results to Logie and colleagues,
[26] we can see that the mean stigma scores in the CF
population for the domains of Disclosures and Public
attitudes were similar to those for the HIV population
(Table 4).
Although our study sample is representative of Canadian
adults living with CF, this study was conducted in a single
center with a limited number of patients. A multi-center
study with patients from different age groups, cultures,
ethnicities, occupations, incomes, and educational back-
grounds is required to further explore stigma and its im-
pact on those living with CF.
This sample was composed primarily of Caucasian
participants (93%) with moderate to high socio-economic
status (50% of participants had a household income of ≥
$61,000). Quittner et al. found [27] that CF patients with
lower socio-economic status and minority populations
experience worse quality of life. Vulnerable population
groups might be at a greater risk of experiencing stigma,
which in turn may impact their adherence to treatment,
health status, and longevity. There is also the question
of generalizability of our results to all CF patients. For
instance, we did not include patients under the age of
18. It is possible that CF stigma could differ depending
on age group (e.g. teenage CF patients may experience
more stigma than adults). A validated CF Stigma Scale






in CF stigma scale; $Q’s 5 and 6 in CF stigma scale.
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youth at risk for lower adherence. Despite demonstrating
acceptable psychometric properties, our brief CF Stigma
Scale needs to be validated in larger populations including
different age groups, with different cultures and languages.
Furthermore, future studies should include additional CF
stigma items which are more relevant to CF symptoms
(e.g. stigma related to persistent cough with heavy sputum
production).
Conclusion
Our study found that stigma is an important and measur-
able construct associated with CF and it significantly im-
pacts the lives of individuals with CF. Although our newly
adapted CF Stigma Scale is easy-to-use and has demon-
strated acceptable psychometric properties, we believe that
it requires further validation in a multi-center study with a
more diverse sample of CF patients. Prospective, longitu-
dinal studies are needed to study stigma and its impact on
important health outcomes such as treatment adherence,
lung function, quality and quantity of life among individuals
who are living with CF.
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